Role of Mesalazine in Acute and Long-Term Treatment of Ulcerative Colitis and Its Complications

References

• Svartz N. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Am J Gastroentero l 1988;83:497–503.
   PubMed Web of Science ®Google Scholar
• Baron JH, Connell AM, Lennard-Jones JE, et al. Sulphasalazine and salicylazosulphadimidin e in ulcerative colitis. Lancet 1962; 1:1094–6.
   PubMed Web of Science ®Google Scholar
• Dick A, Grayson MJ, Carpenter RG, et al. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964; 5:437–42.
   PubMed Web of Science ®Google Scholar
• Misiewicz JJ, Lennard-Jones JE, Connell AM, et al. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;1:185–8.
   Web of Science ®Google Scholar
• Azad Khan AK, Howes DT, Piris J, et al. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 1980;21:232–40.
   PubMed Web of Science ®Google Scholar
• Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892–5.
   Google Scholar
• Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine . J Pharmacol Experiment Ther 1972;181:555–62.
   PubMed Web of Science ®Google Scholar
• Campieri M, Lanfranchi GA, Bazzocchi G, et al. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 1981;2:270–1.
   PubMed Web of Science ®Google Scholar
• Campieri M, Gionchetti P, Belluzzi A, et al. Optimum dosage of 5-aminosalicyli c acid as rectal enemas in patients with active ulcerative colitis. Gut 1991;32:929–31.
   PubMed Web of Science ®Google Scholar
• Biddle WL, Miner PB. Long-term use of mesalamine enemas to induce remission in ulcerative colitis. Gastroenterology 1990;99: 113–8.
   PubMed Web of Science ®Google Scholar
• Campieri M, Paoluzi P, D’Albasio G, et al. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA. Dig Dis Sci 1993;38: 1843–50.
   Google Scholar
• Campieri M, Gionchetti P, Belluzzi A, et al. 5-aminosalicylic acid suppositories in the management of ulcerative colitis. Dis Colon Rectum 1989;32:398–9.
   PubMed Web of Science ®Google Scholar
• Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997;40: 775–81.
   PubMed Web of Science ®Google Scholar
• Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95:1263–76.
   PubMed Web of Science ®Google Scholar
• Nielson OH, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol 1983;16:783–40.
   Web of Science ®Google Scholar
• Staerk Laursen L, Stokholm M, Bukhave K, et al. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990;31:1271–6.
   PubMed Web of Science ®Google Scholar
• Dew MJ, Ryder REJ, Evans M, et al. Colonic release of 5-aminosalicylic acid from an oral preparation in active ulcerative colitis. Br J Clin Pharmacol 1983;16:185–7.
   PubMed Web of Science ®Google Scholar
• Al Mardini H, Lindsay DC, Deighton CM, et al. Effect of polymer coating on faecal recovery of ingested 5-aminosalicylic acid in patients with ulcerative colitis. Gut 1987;28:1084–9.
   PubMed Web of Science ®Google Scholar
• Layer PH, Goebell H, Keller J, et al. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterolog y 1995;108:1427–33.
   PubMed Web of Science ®Google Scholar
• Rao SSC, Dundas SAC, Holdsworth CD, et al. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. Gut 1989;30:675–9.
   PubMed Web of Science ®Google Scholar
• Riley SA, Mani V, Goodman MJ, et al. A comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988;29:669–74.
   PubMed Web of Science ®Google Scholar
• Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazin e in the treatment of active ulcerative colitis : a randomized trial. Br Med J 1989;298:82–6.
   PubMed Web of Science ®Google Scholar
• Meyers S, Sachar DB, Present DH, et al. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized placebo-controlled, doubleblind, dose-ranging clinical trial. Gastroenterology 1987;93: 1255–62.
   Google Scholar
• Zinberg J, Molinas S, Das KM. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am J Gastroenterol 1990;85:562–6.
   Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup D. Coated oral 5-amino-salicylic acid therapy therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317:1625–9.
   Google Scholar
• Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 1991;115:350–5.
   PubMed Web of Science ®Google Scholar
• Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 1993;88:1188–97.
   PubMed Web of Science ®Google Scholar
• Sutherland L, Roth D, Beck P, et al. Oral 5-aminosalicylic for inducing remission in ulcerative colitis (Cochran Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software.
   Google Scholar
• Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92:1867–71.
   PubMed Web of Science ®Google Scholar
• Vecchi M, Meucci G, Gionchetti P, et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a doubleblind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 2001;15:251–6.
   PubMed Web of Science ®Google Scholar
• Marteau P, Crand J, Foucault M, et al. Use of mesalazine slow-release suppositories 1g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut 1998;42:195–9.
   PubMed Web of Science ®Google Scholar
• Rijk MCM, van Lier HJJ, van Tongeren JHM. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. Am J Gastroenterol 1992;87:438–42.
   PubMed Web of Science ®Google Scholar
• Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988;94:1383–9.
   PubMed Web of Science ®Google Scholar
• Mulder CJ, Tytgat GN, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1988;95:1449–53.
   PubMed Web of Science ®Google Scholar
• The Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Ann Intern Med 1996; 124:204–11.
   PubMed Web of Science ®Google Scholar
• Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-releas e mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci 1995;40:296–304.
   PubMed Web of Science ®Google Scholar
• Sutherland L, Roth D, Beck P, et al. Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis (Cochrane Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software.
   Google Scholar
• Kruis W, Brandes JW, Schreiber S, et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther 1998;12:707–15.
   PubMed Web of Science ®Google Scholar
• Green JRB, Holdsworth CD, Lobo AJ, et al. Balsalazide is more effective and better tolerated than mesalamine in acute ulcerative. Gastroenterology 1998;114:15–22.
   PubMed Web of Science ®Google Scholar
• Staerk Laursen L, Stokholm M, Bukhave K, et al. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparation s in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990;31:1270–6.
   Web of Science ®Google Scholar
• Rijk MCM, Van Schaik A, Van Tongeren JHM. Disposition of mesalazine from mesalazine-deliverin g drugs in patients with inflammatory bowel disease, with and without diarrhea. Scand J Gastroentero l 1992;27:863–8.
   PubMed Web of Science ®Google Scholar
• Allgayer H, Ahnfelt NO, Kruis W, et al. Colonic N-acetylatio n of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology 1989;97:38–41.
   PubMed Web of Science ®Google Scholar
• Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-amino-salicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 2000;47:410–14.
   PubMed Web of Science ®Google Scholar
• Klotz U, Maier KE. Pharmacology and pharmacokinetics of 5-aminosalicylic acid. Dig Dis Sci.1987;46S–50S.
   Google Scholar
• Das KM, Eastwood MA, McManus JPA, et al. Adverse reactions during salicylazosulphapyridin e therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973;289:491–5.
   PubMed Web of Science ®Google Scholar
• Taffet SL, Das KM. Sulphasalazine-advers e effects and desensitization. Dig Dis Sci 1983;28:833–42.
   PubMed Web of Science ®Google Scholar
• Sharma BK. Safety profile of the new 5-ASA based compounds. Can J Gastroenterol 1990;4:443–45.
   Google Scholar
• Birnie GG, McLeod TIF, Watkinson G. Incidence of sulpha-salazine-induced male infertility. Gut 1981;22:452–5.
   Google Scholar
• Schwartz AG, Targan SR, Saxon A, et al. Sulfalsalazine-induce d exacerbation of ulcerative colitis. N Engl J Med 1982;306:409–12.
   PubMed Web of Science ®Google Scholar
• Riley SA, LeCarpentier J, Mani V, et al. Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution. Gut 1987;28:1008–12.
   PubMed Web of Science ®Google Scholar
• Mohsen AQM, Mulvey D, Priddle JK, et al. Effects of olsalazine in the jejunum of rat. Gut 1987;28:1474–7.
   PubMed Web of Science ®Google Scholar
• Sturgeon JB, Bhatia P, Hermans D, et al. Exacerbation of ulcerative colitis with mesalamine. Gastroenterology 1995;108:1889–93.
   PubMed Web of Science ®Google Scholar
• Popoola J, Muller AF, Pollock L, et al. Lesson of the week: late onset interstitial nephritis associated with mesalazine treatment. Br Med J 1998;317:795–7.
   PubMed Web of Science ®Google Scholar
• Godet PG, Cowie R, Woodman RC, et al. Pulmonary function abnormalities in patients with ulcerative colitis. Am J Gastroenterol 1997;92:1154–6.
   PubMed Web of Science ®Google Scholar
• Gujral N. Pleuropericarditi s related to the use of mesalamine. Dig Dis Sci 1996;41:624–6.
   PubMed Web of Science ®Google Scholar
• Fiorentini MT, Fracchia M, Galatola G, et al. Acute pancreatitis during oral 5-aminosalicylic acid therapy. Dig Dis Sci 1990;35: 1180–2.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Hamling J, Zehnter E, et al. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 1997;40:761–6.
   PubMed Web of Science ®Google Scholar
• Herrlinger KR, Noftz MK, Fellermann K, et al. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther 2001; 15:363–9.
   PubMed Web of Science ®Google Scholar
• Walker AM, Szneke P, Bianchi LA, et al. 5-aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. Am J Gastroenterol 1997;92:816–20.
   PubMed Web of Science ®Google Scholar
• Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000;118:S68–82.
   PubMed Web of Science ®Google Scholar
• Ireland A, Jewell DP. Mechanism of action of 5-aminosalicylic acid and its derivatives. Clin Sci 1990;78:119–25.
   PubMed Web of Science ®Google Scholar
• Greenfield SM, Punchard NA, Teare JP, et al. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 1993;7:369–83.
   PubMed Web of Science ®Google Scholar
• Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and Nuclear Factor _KB in mouse colonocytes. Gastroenterology 1999;116:602–9.
   Google Scholar
• Wahl C, Liptay S, Adler G, et al. Sulfasalazine: a potent and specific inhibitor of Nuclear Factor Kappa B. J Clin Invest 1998;101:1163–74.
   PubMed Web of Science ®Google Scholar
• Gaginella TS, Walsh RE. Sulfasalazine. Multiplicity of action. Dig Dis Sci 1992;37:801–12.
   PubMed Web of Science ®Google Scholar
• Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14:145–53.
   PubMed Web of Science ®Google Scholar
• Connell WR. Safety of drug therapy for inflammatory bowel disease in pregnant and nursing women. Inflam Bowel Dis 1996; 2:33–47.
   PubMed Web of Science ®Google Scholar
• Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicyli c acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology 1993;105: 1057–60.
   Google Scholar